Recruitment for Phase III clinical trials to assess the efficacy and safety of bepirovirsen is also underway, with results expected in early 2026 (NCT05630807 and NCT05630820)
Among the most frequently reported adverse effects are minor and self-limiting such as local injection site erythema, transient hormonal shifts, and receptor desensitization with prolonged or high-frequency use
How do you envision structuring early-phase studies to satisfy both safety and efficacy expectations for a novel, nonsurgical regenerative therapy
It carries a pharmaceutical generic name, prezatide copper acetate (Iamin), and the formulation that reached controlled human testing under that name was a topical gel but no approval followed
doi: 10.1053/gast.1996.v111.pm8898633, 46
Effects of a supplement containing apoaequorin on verbal learning in older adults in the community